RAYNHAM – Medical robotics company Medrobotics Corp. announced the appointment on March 17 of Russell M. Singleton as the company’s senior vice president of research and development.
The appointment coincides with Medrobotics’ anticipated commercial launches in Europe and the United States of the Flex Robotic System, an “Ear, Nose and Throat” or “ENT” medical device designed to provide minimally invasive access and visualization for surgery in hard-to-reach locations in the throat and voice box.
Minimally invasive surgery procedures, like that enabled by Medrobotics’ robotic-assist platform, are more cost-effective and lead to quicker hospital discharge and faster patient recovery, Medrobotics said.
“We are delighted to have Russ join our growing company,” said Samuel Straface, president and CEO of Medrobotics. “[He] will be leading the transition of the startup R&D team to an agile, commercial powerhouse to enable the expansion of the Flex System.”
Singleton brings more than 30 years of technical and business experience from several industry sectors including medical device, imaging and automation, Medrobotics said. For the past year, he has led the R&D team as acting vice president to prepare the Flex System for commercial launch.
Prior to joining Medrobotics, Singleton served as vice president of R&D for Molecular Dynamics, where his team drove growth through a successful initial public offering and eventual acquisition by GE Healthcare. He has also served in corporate leadership roles as CEO, chief operating officer and general management at various companies.
Singleton holds a bachelor’s degree in electrical engineering from the Pratt Institute in New York and a master’s degree and Ph.D. in electrical engineering from the University of Illinois.
“Building customer-focused technical organizations to achieve market success has been the focus of my career,” said Singleton, “and I am excited to continue that work as a member of an exceptional team at Medrobotics.”
Russell M. Singleton,
Flex Robotic System,
research and development,